BCLI vs. LIAN, ACST, SABS, LPCN, BLRX, TCRT, ZIVO, AVRO, PHXM, and CSBR
Should you be buying Brainstorm Cell Therapeutics stock or one of its competitors? The main competitors of Brainstorm Cell Therapeutics include LianBio (LIAN), Acasti Pharma (ACST), SAB Biotherapeutics (SABS), Lipocine (LPCN), BioLineRx (BLRX), Alaunos Therapeutics (TCRT), ZIVO Bioscience (ZIVO), AVROBIO (AVRO), PHAXIAM Therapeutics (PHXM), and Champions Oncology (CSBR). These companies are all part of the "medical" sector.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, community ranking, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Brainstorm Cell Therapeutics' return on equity of 0.00% beat LianBio's return on equity.
Brainstorm Cell Therapeutics has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500.
LianBio has a consensus target price of $5.33, indicating a potential upside of 1,804.76%. Given LianBio's higher probable upside, analysts clearly believe LianBio is more favorable than Brainstorm Cell Therapeutics.
Brainstorm Cell Therapeutics received 286 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 64.02% of users gave Brainstorm Cell Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote.
14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 5.5% of Brainstorm Cell Therapeutics shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.
In the previous week, Brainstorm Cell Therapeutics had 2 more articles in the media than LianBio. MarketBeat recorded 2 mentions for Brainstorm Cell Therapeutics and 0 mentions for LianBio. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled LianBio'saverage media sentiment score.
Summary
Brainstorm Cell Therapeutics beats LianBio on 7 of the 13 factors compared between the two stocks.
Get Brainstorm Cell Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Brainstorm Cell Therapeutics Competitors List
Related Companies and Tools
